Advertisement

Topics

Charleston's Anti-Emetic/Opioid Combo Flops At US FDA Panel Over Postmarketing, Dosage Concerns

13:18 EST 14 Feb 2018 | SCRIP

Many of the advisory panel members felt the company's proposed buy-back program could not be feasible in practice.

      

Related Stories

 

Original Article: Charleston's Anti-Emetic/Opioid Combo Flops At US FDA Panel Over Postmarketing, Dosage Concerns

NEXT ARTICLE

More From BioPortfolio on "Charleston's Anti-Emetic/Opioid Combo Flops At US FDA Panel Over Postmarketing, Dosage Concerns"

Advertisement
Quick Search
Advertisement
Advertisement